https://www.helus.com/news/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003/ 2026-09-18T19:47:48+00:00 https://www.helus.com/news/cybin-receives-fda-breakthrough-therapy-designation-for-its-novel-psychedelic-molecule-cyb003-and-announces-positive-four-month-durability-data-in-major-depressive-disorder/ 2026-09-21T21:12:06+00:00 https://www.helus.com/news/announces-oversubscribed-private-placement-of-u-s-150-million/ 2026-09-22T20:52:58+00:00 https://www.helus.com/news/helus-pharma-to-participate-at-the-morgan-stanley-24th-annual-global-healthcare-conference-in-new-york/ 2026-09-22T22:50:37+00:00 https://www.helus.com/news/helus-pharma-to-participate-at-the-h-c-wainwright-28th-annual-global-investment-conference-in-new-york/ 2026-09-22T22:50:37+00:00 https://www.helus.com/news/helus-pharma-to-participate-at-the-2026-cantor-global-healthcare-conference-in-new-york/ 2026-09-22T22:50:37+00:00 https://www.helus.com/news/helus-pharma-appoints-regina-donohue-as-chief-people-officer-and-suresh-durgam-m-d-to-its-scientific-advisory-board/ 2026-09-22T22:50:37+00:00 https://www.helus.com/news/helus-pharma-presents-new-analyses-on-hlp003-in-major-depressive-disorder-at-psych-congress-2026/ 2026-09-22T22:50:37+00:00 https://www.helus.com/news/helus-pharma-to-participate-at-the-td-cowen-6th-annual-novel-mechanisms-in-neuropsychiatry-summit/ 2026-09-22T22:50:37+00:00 https://www.helus.com/news/helus-pharma-announces-results-of-annual-and-special-meeting-of-shareholders-and-effective-date-for-legal-name-change/ 2026-09-22T22:50:37+00:00 https://www.helus.com/news/helus-pharma-reports-first-quarter-fiscal-2027-financial-results-and-recent-business-highlights/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-to-participate-at-the-canaccord-genuity-46th-annual-growth-conference-in-boston/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-appoints-michael-halstead-as-chief-executive-officer/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-in-adjunctive-treatment-of-major-depressive-disorder-ahead-of-schedule/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-reports-recent-business-highlights-and-fiscal-year-2026-financial-results/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-announces-closing-of-us50-million-underwritten-offering/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-announces-us50-million-underwritten-offering/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-provides-update-on-approach-phase-3-trial-enrollment-progress/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-to-participate-in-the-h-c-wainwright-7th-annual-neuro-perspectives-conference/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-to-participate-in-the-jefferies-global-healthcare-conference-in-new-york/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-to-participate-at-the-29th-annual-milken-institute-global-conference/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-partners-with-tara-mind-to-advance-veteran-mental-health/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-strengthens-scientific-advisory-board-with-addition-of-dr-robert-langer-and-dr-stephen-brannan/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-expresses-support-for-executive-order-advancing-psychedelic-research-and-regulatory-pathways-for-serious-mental-health-conditions/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-announces-chief-executive-officer-transition-eric-so-to-resume-role-as-interim-chief-executive-officer/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-strengthens-medical-leadership-by-appointing-dr-ken-kramer-as-senior-vice-president-medical-affairs/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-strengthens-executive-team-with-appointment-of-jill-conwell-as-chief-people-officer/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-announces-topline-results-in-phase-2-signal-detection-study-for-hlp004-in-patients-with-generalized-anxiety-disorder/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-chair-of-the-scientific-advisory-committee/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/nature-medicine-publishes-helus-pharmas-randomized-placebo-controlled-phase-2a-trial-of-spl026-in-major-depressive-disorder/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-reports-third-quarter-fiscal-year-2026-financial-results-and-recent-business-highlights/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-appoints-michael-cola-as-chief-executive-officer-to-lead-next-phase-of-scale-and-execution/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/helus-pharma-propels-therapeutic-innovation-in-mental-health-and-commences-trading-on-nasdaq/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-initiates-at-the-market-equity-program-of-up-to-us100-million/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-to-transfer-u-s-stock-exchange-listing-to-nasdaq/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-reports-second-quarter-fiscal-year-2026-financial-results-and-recent-business-highlights/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-to-participate-in-the-jefferies-global-healthcare-conference-in-london/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-to-announce-second-quarter-financial-results-and-provide-business-update-on-november-13-2025/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-to-participate-at-the-2025-milken-institute-future-of-health-summit/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-announces-closing-of-175-million-registered-direct-offering/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-announces-175-million-registered-direct-offering/ 2026-09-22T22:50:38+00:00 https://www.helus.com/news/cybin-highlights-neuropsychiatry-platform-and-upcoming-clinical-milestones/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-td-cowens-5th-annual-novel-mechanisms-in-neuropsychiatry-epilepsy-summit/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-completes-enrollment-in-phase-2-study-evaluating-cyb004-for-the-treatment-of-generalized-anxiety-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-the-cantor-global-healthcare-conference-2025/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-announces-senior-leadership-changes/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-receives-australian-approval-for-embrace-a-multinational-pivotal-study-evaluating-cyb003-for-the-adjunctive-treatment-of-major-depressive-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-announces-results-of-annual-meeting-of-shareholders/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-reports-important-progress-on-key-milestones-and-first-quarter-fiscal-year-2026-financial-results/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-receives-european-approval-for-embrace-a-multinational-phase-3-study-evaluating-cyb003-for-the-adjunctive-treatment-of-major-depressive-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-receives-uk-mhra-approval-to-commence-embrace-a-multinational-pivotal-study-evaluating-cyb003-for-the-adjunctive-treatment-of-major-depressive-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-announces-financing-of-up-to-us500-million-aggregate-principal-amount-of-convertible-debentures/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-reports-fiscal-year-2025-financial-results-and-recent-business-highlights/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-provides-corporate-update-and-highlights-positive-regulatory-signals-for-psychedelic-therapeutics/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-the-h-c-wainwright-6th-annual-neuro-perspectives-conference/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-the-2025-psychedelic-science-conference/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-announces-additional-u-s-patent-supporting-its-cyb004-program-in-phase-2-development-for-generalized-anxiety-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-water-tower-research-fireside-chat-on-may-29-2025/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-applauds-fda-commissioner-dr-martin-makarys-call-to-accelerate-and-prioritize-research-on-psychedelic-therapeutics/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-engages-thermo-fisher-scientific-to-provide-u-s-based-manufacturing-for-its-cyb003-program-for-the-adjunctive-treatment-of-major-depressive-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-the-alliance-global-partners-healthcare-company-showcase/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-announces-additional-u-s-patent-supporting-its-cyb003-breakthrough-therapy-program-in-phase-3-development-for-major-depressive-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-at-the-28th-annual-milken-institute-global-conference/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-announces-additional-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-phase-3-program-evaluating-cyb003/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-partners-with-osmind-to-accelerate-commercial-preparation-for-its-clinical-stage-psychiatry-programs/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-reports-third-quarter-fiscal-year-2025-financial-results-and-recent-business-highlights/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-launches-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for-the-adjunctive-treatment-of-major-depressive-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-highlights-2024-accomplishments-and-upcoming-milestones-for-2025/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-announces-poster-presentations-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting-including-cyb003-12-month-efficacy-results/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-participate-in-water-tower-research-fireside-chat-on-december-11-2024/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-breakthrough-12-month-efficacy-in-treating-major-depressive-disorder/ 2026-09-22T22:50:39+00:00 https://www.helus.com/news/cybin-to-present-12-month-phase-2-data-for-cyb003-in-major-depressive-disorder-on-november-18-2024/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for-the-adjunctive-treatment-of-major-depressive-disorder-and-reports-second-quarter-financial-results/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-at-the-2024-milken-institute-future-of-health-summit/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-announces-grant-of-first-u-s-composition-of-matter-patent-in-support-of-its-cyb005-phenethylamines-program/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-in-water-tower-research-fireside-chat-on-october-8-2024/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-expands-clinical-team-to-support-cyb003-phase-3-program/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-in-the-td-cowen-4th-annual-novel-mechanisms-in-neuropsychiatry-summit/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-announces-completion-of-previously-announced-share-consolidation/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-provides-corporate-update-on-upcoming-clinical-milestones/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-announces-results-of-annual-and-special-meeting-of-shareholders-and-share-consolidation/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-announces-completion-of-fda-type-b-initial-breakthrough-therapy-meeting-and-plans-for-cyb003-phase-3-program-in-major-depressive-disorder/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-reports-first-quarter-fiscal-year-2025-financial-results-and-recent-business-highlights/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-in-the-canaccord-genuity-44th-annual-growth-conference/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-reports-fiscal-year-2024-financial-results-and-recent-business-highlights/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-in-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-appoints-dr-atul-mahableshwarkar-m-d-as-senior-vice-president-clinical-development/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-at-the-pathways-to-access-summit-and-the-interdisciplinary-conference-on-psychedelic-research-2024/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-in-the-alliance-global-partners-healthcare-company-showcase-2/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-provides-corporate-update-and-highlights-upcoming-clinical-milestones/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-participate-at-the-27th-annual-milken-institute-global-conference/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-announces-publication-of-research-manuscript-in-the-journal-of-medicinal-chemistry/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-announces-grant-of-additional-u-s-patent-in-support-of-its-cyb003-breakthrough-therapy-program-for-major-depressive-disorder/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-present-at-the-2024-bloom-burton-co-healthcare-investor-conference/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-announces-closing-of-the-oversubscribed-private-placement-of-u-s-150-million/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-to-present-at-public-ventures-discovery-day-on-march-19th-in-dallas/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-initiates-phase-2-proof-of-concept-study-of-cyb004-in-generalized-anxiety-disorder/ 2026-09-22T22:50:40+00:00 https://www.helus.com/news/cybin-announces-positive-end-of-phase-2-meeting-with-fda-for-cyb003-in-major-depressive-disorder-and-phase-3-program-design/ 2026-09-22T22:50:40+00:00